These resistance mechanisms include enhanced drug efflux through P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) [45], increased DNA repair capacity [46], altered apoptotic signaling [47], and a modified tumor microenvironment [48]. This evidence concerns the gene ABCG2 and neoplasm.